Karnataka has urged the Centre to extend price-control measures beyond cancer medicines to other high-cost, life-saving drugs used to treat cardiac and kidney diseases, following the National Pharmaceutical Pricing Authority’s (NPPA) in-principle approval to cap trade margins on certain non-scheduled anti-cancer medicines at 30% of their maximum retail price (MRP).
Addressing presspersons in Bengaluru, Health Minister U.T. Karnataka had sought the inclusion of advanced chemotherapy, targeted therapy and other expensive cancer medicines under the ambit of the Drugs (Prices Control) Order, along with a comprehensive cap on trade margins for high-cost and life-saving medicines. The State said the proposed 30% trade-margin cap on non-scheduled anti-cancer medicines should be followed by wider action to cover other essential, high-cost medicines, including those used in cardiac and kidney treatment, so that the benefits of price rationalisation reach patients directly.
The Centre estimates that the measure could reduce the MRP of several anti-cancer medicines by 20% to 70%, potentially saving patients around ₹2,500 crore. Citing examples, the Minister said a cancer drug/injection costing around ₹3,250 was reportedly priced at ₹23,347. Medicines with a landing cost of about ₹3,000 are being sold at a cost of ₹27,000. Under the 30% trade-margin cap, the maximum price of a medicine would depend on its applicable pricing base and can substantially reduce out-of-pocket expenditure for patients, he explained.
Khader said price rationalisation should translate into direct savings for patients, and urged the Union government to extend similar measures to other essential medicines where high treatment costs place a burden on patients. “The financial strain of cancer treatment often pushes families into debt, making it inevitable for them to exhaust their savings and sell assets to meet medical expenses,” Mr. Khader said.
The Ministry of Health and Family Welfare has been asked to constitute an expert committee under the Directorate General of Health Services to recommend the anti-cancer medicines to be brought under price control. The committee is expected to submit its report by October 14.
